The compound you described, **2-(2,4-dioxo-3-thiazolidinyl)-N-[4-(4-morpholinyl)phenyl]acetamide**, is also known as **TZD-8**. It's a synthetic compound with a unique structure containing thiazolidinedione (TZD) and morpholine moieties.
**Importance in Research:**
TZD-8 has been investigated for its potential therapeutic applications, particularly in the field of **inflammation and pain management**.
* **Anti-inflammatory Activity:** TZD-8 has shown promising anti-inflammatory effects in various preclinical studies. Its mechanism of action is linked to the inhibition of pro-inflammatory mediators like TNF-alpha and IL-1β, contributing to its anti-inflammatory potential.
* **Analgesic Activity:** Some research suggests that TZD-8 may possess analgesic properties, effectively reducing pain perception. This could be due to its ability to modulate the activity of pain signaling pathways in the body.
**Current Research and Potential Applications:**
* **Treatment of Inflammatory Conditions:** TZD-8 is currently being explored as a potential therapeutic agent for the management of inflammatory diseases like arthritis, inflammatory bowel disease, and skin conditions.
* **Pain Relief:** Research is ongoing to investigate its efficacy as a pain reliever for conditions like osteoarthritis and chronic pain syndromes.
**Important Note:**
While promising, TZD-8 is still in the early stages of research. It is crucial to note that the compound has not yet been approved for any therapeutic use in humans. Further studies are necessary to evaluate its safety and efficacy in clinical settings.
**In Conclusion:**
2-(2,4-dioxo-3-thiazolidinyl)-N-[4-(4-morpholinyl)phenyl]acetamide (TZD-8) is a synthetic compound with potential anti-inflammatory and analgesic properties. Research is ongoing to investigate its therapeutic value in treating inflammatory conditions and pain. However, more studies are needed to validate its safety and efficacy before it can be considered for clinical use.
ID Source | ID |
---|---|
PubMed CID | 649187 |
CHEMBL ID | 1480015 |
CHEBI ID | 109212 |
Synonym |
---|
AKOS000420478 |
MLS000068352 |
BAS 06660432 |
2-(2,4-dioxo-thiazolidin-3-yl)-n-(4-morpholin-4-yl-phenyl)-acetamide |
smr000013850 |
MLS002537544 |
CHEBI:109212 |
2-(2,4-dioxo-1,3-thiazolidin-3-yl)-n-(4-morpholin-4-ylphenyl)acetamide |
CCG-117318 |
HMS2333N24 |
STL375833 |
2-(2,4-dioxo-1,3-thiazolidin-3-yl)-n-[4-(morpholin-4-yl)phenyl]acetamide |
CHEMBL1480015 |
2-(2,4-dioxo-3-thiazolidinyl)-n-[4-(4-morpholinyl)phenyl]acetamide |
Q27188286 |
SR-01000324292-1 |
sr-01000324292 |
Class | Description |
---|---|
morpholines | Any compound containing morpholine as part of its structure. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
GLS protein | Homo sapiens (human) | Potency | 31.6228 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 15.8489 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |